Business
AZN harmonises listing structure
AstraZeneca plans to harmonize its listing structure across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. The proposal involves a direct listing of AstraZeneca shares on the NYSE, replacing the existing US listing of American Depositary Receipts (ADRs) on Nasdaq. Following this change, shareholders will be able to trade AstraZeneca ordinary shares across all three exchanges. The company will remain headquartered and tax resident in the UK, and continue to be included in the FTSE 100 index and the OMX Stockholm 30 index. A general meeting will be held on Monday 3 November 2025 at 2:30 p.m. (GMT) to discuss the proposed Harmonised Listing Structure. Disclaimer*
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n \n \n29 September 2025\n \nAstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange\n \nHarmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs\n \nAstraZeneca continues to be listed, headquartered and tax resident in the UK\n \nAstraZeneca plans to harmonise its share listing structure to deliver a global listing for global investors in a global company. The Board of AstraZeneca is recommending to shareholders a Harmonised Listing Structure for the Company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO) and the New York Stock Exchange (NYSE). \nThis requires upgrading AstraZeneca's existing US equity listing by way of a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing US listing of AstraZeneca ADRs on Nasdaq. Following implementation of the Harmonised Listing Structure, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the LSE, STO and NYSE.\nMichel Demaré, Chair, AstraZeneca said: \"Today we set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca's exciting future.\"\nAstraZeneca's scientific and commercial achievements have been underpinned by its continuous adaptation to a rapidly changing and dynamic industry environment, including diversifying its access paths to capital markets. The US has the world's largest and most liquid public markets by capitalisation, and the largest pool of innovative biopharma companies and investors. The Board is determined to ensure that the AstraZeneca Group has the flexibility to access the broadest available pool of capital, including in the US, which today's announcement will make possible.\nThe Harmonised Listing Structure will not change AstraZeneca's current status as a UK listed, headquartered and tax resident company which will continue to be included in the ...